Oncology Today with Dr Neil Love Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
May 5, 2025
Dr. Rebecca Dent, a breast cancer specialist from the National Cancer Centre in Singapore, and Dr. Nancy Lin, an expert from the Dana-Farber Cancer Institute, delve into groundbreaking 2024 research on breast cancer treatments. They discuss the transformative PATINA trial for triple-positive breast cancer and advancements in HER2-positive therapies that enhance survival rates. Topics also include strategic insights on adjuvant therapy for ER-positive patients, emerging options like ribociclib, and the impact of innovative treatments on patient care.
AI Snips
Chapters
Transcript
Episode notes
PATINA Trial's Breakthrough in Triple Positive BC
- The PATINA trial showed a significant progression-free survival benefit adding palbociclib to HER2-directed therapy plus endocrine therapy in triple positive breast cancer.
- This suggests overcoming resistance via CDK4/6 inhibition may change maintenance therapy approaches in this subgroup.
Tailoring CDK4/6 Use by Patient Profile
- Choose CDK4/6 inhibitors based on patient comorbidities and side effect profiles, e.g., avoid abemaciclib in those with GI issues.
- Implement dose escalation strategies to improve tolerability, as supported by ongoing trials like TRADE.
Endocrine+CDK vs Chemotherapy Decisions
- Consider endocrine plus CDK4/6 inhibitors over chemotherapy even in some visceral disease cases unless rapid response is essential.
- Assess urgency and patient's preferences carefully to decide therapy in metastatic ER-positive breast cancer.